Host Defense Peptides as Effector Molecules of the Innate Immune Response: A Sledgehammer for Drug Resistance? by Steinstraesser, Lars et al.
Int. J. Mol. Sci. 2009, 10, 3951-3970; doi:10.3390/ijms10093951 
 
International Journal of 
Molecular Sciences 
ISSN 1422-0067 
www.mdpi.com/journal/ijms 
Review 
Host Defense Peptides as Effector Molecules of the Innate 
Immune Response: A Sledgehammer for Drug Resistance? 
Lars Steinstraesser 
1,*, Ursula M. Kraneburg 
1, Tobias Hirsch 
1, Marco Kesting 
2, Hans-Ulrich 
Steinau 
1, Frank Jacobsen 
1 and Sammy Al-Benna 
1 
1  Department of Plastic and Reconstructive Surgery, BG University Hospital Bergmannsheil, Ruhr 
University Bochum, Bochum, Nordrhein-Westfalen, Germany; E-Mails: u.kraneburg@yahoo.de 
(U.M.K.); tobias.hirsch@ruhr-uni-bochum.de (T.H.); hans-ulrich.steinau@bergmannsheil.de  
(H.-U.S.); frank.jacobsen@ruhr-uni-bochum.de (F.J.); sammy.al-benna@ruhr-uni-bochum.de 
(S.A.B.) 
2  Department of Oral and Maxillofacial Surgery, Technische Universität München, Ismaninger Str. 
22, München, Germany; E-Mail: marco.kesting@gmx.de (M.K.) 
*  Author to whom correspondence should be addressed;  
E-Mail: lars.steinstraesser@ruhr-uni-bochum.de (L.S.); Tel. +49-234-302-3442;  
Fax: +49-234-302-6379. 
Received: 3 July 2009; in revised form: 17 August 2009 / Accepted: 9 September 2009 /  
Published: 9 September 2009 
 
Abstract:  Host defense peptides can modulate the innate immune response and boost 
infection-resolving immunity, while dampening potentially harmful pro-inflammatory 
(septic) responses. Both antimicrobial and/or immunomodulatory activities are an integral 
part of the process of innate immunity, which itself has many of the hallmarks of 
successful anti-infective therapies, namely rapid action and broad-spectrum antimicrobial 
activities. This gives these peptides the potential to become an entirely new therapeutic 
approach against bacterial infections. This review details the role and activities of these 
peptides, and examines their applicability as development candidates for use against 
bacterial infections. 
Keywords:  host defense peptides; sepsis; innate immunity; antimicrobial peptides; 
bacterial infection; inflammation 
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1. Introduction 
 
Throughout our history we have placed human health above our concern for the survival of 
pathogenic micro-organisms. We have sought the elimination of infectious diseases and the destruction 
of the micro-organisms that cause those diseases. Antibiotics and vaccines were one of the crown 
jewels of medical progress in the 20th century. At the start of the 21st century, we find ourselves in a 
peculiar and perplexing situation in that the pharmaceutical pipeline appears to have become less and 
less productive. Unfortunately, the initial promise of these miracle drugs was soon set back to some 
degree by the emergence of resistance to these agents among a broad variety of bacterial species and 
our ability to identify new agents to cope with the resistant bacteria is diminishing. Due to the threat of 
development of antimicrobial resistance as a result of misuse and/or overuse of antimicrobial agents, 
health care professionals should exercise caution and discretion when treating such infections with 
these agents [1].   
In the 1940s hospitals in Europe and North America reported that bacterial infections were resistant 
to penicillin [2]. It took less than one year for resistance to penicillin to develop and interestingly the 
first description of penicillinase occurred 1 year before penicillin was ever used clinically [2]. 
Following this the first methicillin-resistant Staphylococcus aureus (MRSA) was identified in the 
1960s [3]. From 1980-1986, there was a resurgence of infective diseases and mortality from these 
diseases in the United States of America increased by 64% to levels not seen since the 1940s [4]. The 
World Health Organization has stated that MRSA infections are now endemic worldwide. The rate of 
MRSA in Canadian hospitals increased from 0.46 to 5.90 per 1,000 admissions between 1995 and 
2004 [5], which constituted an enormous increase in hospitalization and treatment costs, with the total 
cost per infected MRSA patient averaging $12,216 [6]. In 2002, the first clinical isolate of 
vancomycin-resistant S. aureus (VRSA) was identified [7].The struggle to gain the upper hand against 
infections continues to the present day. Medical advances against infectious disease have been 
hindered by changes in the patient population. Immunocompromised hosts now constitute a significant 
proportion of the seriously infected population, including patients that have been immunosuppressed 
by clinicians to prevent the rejection of transplants and to treat inflammatory diseases. 
Over the past 50 years health care professionals and researchers have been fighting the increasing 
number of drug resistant bacteria, since such pathogens present significant clinical problems in 
managing infections that were easy treatable years before. Diseases once thought to have been nearly 
eradicated from the developed world, including tuberculosis, cholera and rheumatic fever, have risen 
again with renewed ferocity. These infectious diseases are major causes of morbidity and mortality 
worldwide. Therefore, a new paradigm in the treatment of infectious diseases is needed that is not 
compromised by the development of increasingly aggressive resistant strains of microbial pathogens 
and the rapid reduction of therapeutic efficacies of the available antibiotic therapies.  
The increasing resistance of bacteria to conventional antibiotics has encouraged strong efforts to 
develop antimicrobial agents with new mechanisms of action. Perhaps research has now entered the 
post-antibiotic era, as there are currently major initiatives to develop new therapies, including host 
defense peptides (HDPs), which combine antimicrobial activity with angiogenic, immunomodulating 
and anti-inflammatory properties [8-10]. None of the clinically used antibiotics possess these features. Int. J. Mol. Sci. 2009, 10                 
 
 
3953
Equally important as their roles in the mediation of innate immune response are the roles that each 
type plays in recruiting B and T lymphocytes of the adaptive immune system to engage in specific 
antipathogen response. Their functions include antimicrobial, anti-endotoxic, anti-inflammatory 
activities and promoting wound healing. This aim of this review is to discuss the suitability of HDPs as 
potential therapeutic tools to treat infectious disease. 
 
2. Cationic Host Defense Peptides 
 
As an evolutionary co-development to prevent microbial colonization and tissue damage the 
production of HDPs of various structural classes have been isolated from a wide range of animal, 
plant, fungal and bacterial species [12]. As they have successfully retained their antimicrobial activity 
for millions of years, certain HDPs act as natural antibiotics, showing an exceptionally broad spectrum 
of activity, ranging from Gram-negative and Gram-positive bacteria to fungi and viruses [13-16]. It is 
conceivable that the relatively rapid development of microbial-resistance mechanisms may have 
evolved alongside the variety and high number of HDPs. At present, more than 1,220 HDPs are 
known, including over 940 HDPs in eurkaryotic organisms, listed in three databases [17-19]. 
According to their molecular composition, size, conformational structure, or predominant amino 
acid structure, HDPs can be divided into three main classes: linear α-helical structures without 
disulphide bonds (for example, cathelicidins, magainins and cecropins), β-sheet structures stabilized 
by characteristic disulfide bridges (for example, defensins), with predominance of one or more amino 
acids, and loop-structured peptides [13,20-22].  
These latter two human classes constitute the less well-studied cathelicidins and defensins (Table 1) 
[23,24]. The α-helical structured hCAP-18, also known as LL-37, was first described in 1995 and is 
the only investigated antimicrobial peptide member of the cathelicidin family. Cathelicidins are a 
family of antimicrobial proteins found in most mammalian species. They consist of a highly conserved 
N-terminal domain, cathelin, and a variable C-terminal peptide, which is proteolytically released upon 
demand. It is mainly produced by leucocytes, epithelial cells and mucosal cells where it is stored in 
specific granules [25]. Its cationic C-terminal 37 amino acid domain, LL-37 displays broad 
antimicrobial activity mediated through direct interaction with and disruption of the microbial cell 
membrane. The enzyme responsible for cleavage of the proprotein in neutrophils is serine proteinase 3. 
In skin, the serine proteases kallikrein 5 and 7 were recently reported to mediate alternative processing 
of hCAP18 generating several novel peptide fragments, suggesting that peptide profiles may differ 
between tissues and biological conditions. This opens up a potential new area of research since their 
functional profile may differ. In addition to being antimicrobial, LL-37 is implicated in diverse 
biological processes, such as angiogenesis, chemotaxis, cytokine production, histamine release and 
wound healings [25-28,100]. Due to the simple linear structure of hCAP-18/LL-37 some bacteria are 
already able to inactive it by producing peptidases and proteases which degrades the peptide, for 
instance the V8 and aureolysin proteases from S. aureus and the outer-membrane protease PgtE from 
Salmonella enterica serovar typhimurium [29,30].  
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Table 1. Functions of HDPs in combating infections and modulating the immune response. 
Host Defense Peptide  Site of Expression 
Immunomodulatory 
Function 
Human cathelicidin (cationic, α-helical structure, consist of a highly conserved N-
terminal domain, cathelin, and a variable C-terminal peptide) [13, 16, 23, 25, 51, 53, 54, 
75, 79, 95, 100] 
hCAP18/LL37 
 
 
Neutrophils, keratinocytes, 
epithelial cells of skin and 
testis, gastrointestinal and 
respiratory tract, mast cells, 
monocytes/macrophages, 
CD4+ cells, myelocytes, 
wound and blister fluid, cervix 
vagina,  esophagus, mouth, 
tongue 
Broad antimicrobial activity, 
antiviral and antifungal 
activity, endotoxin-binding 
properties, modulation of pro-
inflammatory response, 
chemotactic, influence of cell 
proliferation and 
differentiation, promoting 
wound healing and 
angiogenesis, induction of 
gene expression, induction of 
adaptive immunity 
Human α-Defensins (human neutrophil proteins; closely-related to human cathelicidin, 
Cys–Arg-rich, cationic, disulfide bridges, β-sheet structure) [22, 36-40] 
HNP-1 to -4 
 
Azurophilic granules of 
neutrophil granulocytes, B-
cells, natural killer cells, T-
cells 
Killing of phagocytosed 
microorganisms, antimicrobial 
activity against Gram-positive 
and gram-negative bacteria, 
antiviral (HSV, CMV, HIV-1) 
properties, exotoxin-
inactivation, chemotactic for 
monocytes, T-cells, immature 
dendritic cells, upregulation of 
tumor-necrosis factor α (TNF-
α) and IL-1, downregulation of 
complement activation, 
promotion of DC activation 
HD-5 and -6  
Paneth cells granules of 
neutrophils, natural killer cells 
Microbicidal activity against 
Escherichia coli, 
Staphylococcus aureus, 
Listeria monocytogenes, 
Salmonella typhimurium, C. 
albicans, induction of IL-8 
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Table 1. Cont. 
Human-β-Defensins (closely-related to human cathelicidin, Cys–Arg-rich, cationic, 
disulfide bridges, β-sheet structure) [13, 34-36, 61, 105] 
hBD-1 
CD4+ and CD8+ T-cells, 
dendritic cells, epithelial cells 
of skin, respiratory, 
gastrointestinal and urogenital 
tract, trachea, uterus, pancreas, 
thymus, testis, vagina, gingival 
intestine, conjunctiva, cornea, 
lacrimal and buccal mucosa, 
tongue, salivary gland, 
mammary glands, limb joints, 
astrocytes, microglia 
Broad antimicrobial activity, 
antiviral and antifungal 
activity, chemotactic, 
induction of chemokines and 
cytokines, recruiting immune 
cells, induction of adaptive 
immunity and pro-
inflammatory cytokines such 
as IL-8, -18 and -20, 
degranulation of mast cells, 
promotion of phagocytosis, 
induction of dendritic cell 
maturations by TLR-4, LPS 
and LTS binding properties, 
inhibition of MMP- inhibitors 
(TIMP-1/-2) 
hBD- 2 
Mast cells, CD4+ and CD8+ 
T- cells, dendritic cells, skin, 
oral, pulmonl, gastric 
epithelia, conjuctiva, cornea, 
astrocytes 
hBD- 3 
Monocytes, CD4+ T-cells, 
oral, respiratory tract, 
gastrointestinal tract, urinary 
and skin epithelial cells, 
uterus, placenta, testis, 
esophagus, heart, neutrophils, 
trachea, skeletal muscle, 
tongue, kidney, liver 
gastrointestinal tract, oro-
pharynx, tonsils, salivary 
glands  
 
Defensins are a group of closely-related, Cys–Arg-rich, cationic HDPs comprised of 29 to 45 amino 
acid residues. The six conserved Cys residues that are a characteristic feature of defensins form three 
intramolecular disulfide bridges between the NH2- and COOH-terminal regions of the peptide, creating 
a cyclic, triple-stranded, amphiphilic β-sheet structure, making up the characteristic “defensin-like” 
fold and spatially separated hydrophobic and hydrophilic regions. These three intramolecular 
disulphide bridges stabilize its β-sheet structures and increase resistance to proteolysis, but also reduce 
the flexibility [31,32], although disulphide bridges are not necessarily essential for the antimicrobial 
activity of defensins [33]. Defensins can be divided into α- and β-defensins; the disulfide 
connectivities in α-defensins are Cys1–Cys6, Cys2–Cys4 and Cys3–Cys5 (the number indicates the 
location of the Cys residue in the amino acid sequence from the N-terminus), while in β-defensin they 
are Cys1–Cys5, Cys2–Cys4 and Cys3–Cys6 [34]. Int. J. Mol. Sci. 2009, 10                 
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In human neutrophils, defensins comprise 30–50% of the granule proteins [35,36]. In human skin, 
defensins are produced mainly by keratinocytes, neutrophils, sebocytes or sweat glands [22] and are 
either expressed constitutively or after an inflammatory stimulus. α-Defensins secreted by neutrophils 
can be detected in biological fluids [37-40]. The concentration of α-defensins in human plasma under 
normal physiological conditions is about 40 ng/mL, as measured by ELISA [37]. This concentration 
increases 2- to 4-fold in patients with an inflammatory syndrome and reaches micromolar 
concentrations in septic patients [38]. In the plasma, α- and β- defensins bind unspecifically to high 
mass plasma proteins such as serum albumin, α2-macroglubulin and C1 complement, which decreases 
their anti-viral and anti-tumour activity [39,40]. Both α- and β- defensins have been found in human 
body fluids during inflammatory lung diseases, urinary tract infection and in tears after ocular surface 
surgery [22,41-46]. The relative structural stability of defensins has not caused their loss during the 
course of evolution and it can therefore be proposed that certain activities, such as the interaction with 
dedicated receptors, might have favored the development of more flexible peptides such as   
hCAP/LL-37. A better understanding of the function of hCAP/LL-37 and defensins in immunity has 
implications for the development of potential clinical therapeutics for the treatment of infection   
or cancer. 
Recent studies have investigated the dichotomous role of HDPs in cancer biology. It has been 
shown that hCAP/LL-37 activates tumor cells resulting in increased cell growth in vitro and in an 
animal model [47,48]. In contrast, Bose et al. demonstrated that human beta defensin-1 (hBD1) 
induces rapid cytolysis of prostate cancer cells and that the PAX2 oncogene suppresses hBD1 
expression in prostate cancer [49]. 
 
3. Activities of Host Defense Peptides 
 
A microbial pathogen has the potential to enter any part of a host organism. Damaged skin can be a 
major portal of entry and allow multiplication of pathogens; tetanus and burn wound infections are 
clear examples. As mentioned previously, the innate immune system is the first line of defense as the 
adaptive immune response is not rapid enough to control the onset of infections. HDPs play a 
significant role in this process [14,15,50,51]. Their characteristics, including angiogenesis,   
anti-microbial, chemotaxis, cytokine production, histamine release, lipopolysaccharide (LPS)-binding 
properties and other immunomodulatory activities can lead to control infection and allow the 
appropriate activation of adaptive immune responses [52-54]. 
A correlation between the severity of the disease and the level of HDP production has been 
demonstrated in several studies. [55,56] Morrison et al. could demonstrate increasing susceptibility to 
infections caused by S. aureus in ß-defensin-2 knockout mice and isolated Dermcidin (DCD) peptide 
DCD-1L produced by eccrine sweat glands in the skin has been shown to stimulate the production of 
cytokines/chemokines by human keratinocytes [55,56]. Reduced expression of DCD in sweat of 
patients with atopic dermatitis has been associated with high susceptibility of these patients to skin 
infections and altered skin colonization [57]. In contrast, overexpression or exogenous application of 
HDPs have a protective effect in animals [51,58,59]. Clinically overexpresson can lead to increased 
protection against skin infections as seen in patients with psoriasis, rosacea and inflammatory skin-
diseases such as acne vulgaris which is rarely associated with clinical superinfection [60]. The Int. J. Mol. Sci. 2009, 10                 
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expression of many HDPs increases during infection and inflammation. For instance HBD-2 is 
upregulated in various cell types such as monocytes, epithelial cells and keratinocytes during bacterial 
infections and by stimulation from different bacterial components that activate the Toll-like receptor 
(TLR) to nuclear factor (NF)-kB pathway [61-63]. In addition, decreased defensin levels in burn injury 
may facilitate infection and subsequent sepsis [64]. 
Human skin is always in contact with the environment and is covered with a characteristic 
microflora of non pathogenic bacteria (commensals). HDPs are mainly associated with inflammatory 
lesions and wounds, but some are also focally expressed in skin, including β-defensins, RNase 7,  
S100-protein Psoriasin and hCAP-18/LL-37 in the absence of inflammation [22]. This may be due to 
an imbalance between impaired defense and increased susceptibility to infection [16].  
Hancock  et al. demonstrated that HDP antimicrobial activity was not necessarily required for 
protection in vivo and an HDP with no antimicrobial activity was found to be protective in animal 
models of Staphylococcus aureus and Salmonella enterica infection, implying that a host defense 
peptide can protect by exerting immunomodulatory properties [54]. HDPs have hitherto been 
considered for their antibiotic properties, however, some of them, particularly defensins, evolved to 
also exhort a large variety of other functions [54]. This raises the question as to what HDPs really are: 
are they principally antimicrobials or are they modulators of innate and adaptive immune responses, or 
both? It has been proposed that some HDPs, for example defensins, have traded their antibiotic 
capacities to acquire immunomodulatory functions presumably to reverse suppressive microbial 
functions and to elicit more robust host inflammatory and adaptive responses [54]. 
 
4. Strategies and Functional Properties of Host Defense Peptides 
 
HDPs belong to the most rapid evolving group of mammalian peptides [65,66] and have developed 
broad-spectrum antimicrobial properties, such as direct killing of Gram-negative and Gram-positive 
bacteria, fungi, and parasites [12,67]. A therapeutic goal is to engineer peptides with high efficacy and 
target specificity. In order to achieve this goal, the mechanisms of actions of the HDPs must   
be understood. 
There are distinctive different external and internal target mechanisms. One can distinguish 
between peptides that permeabilize and/or disrupt the bacterial cell membrane and peptides that 
translocate through the cell membrane and interact with a cytosolic target [68-70]. 
The antimicrobial activity of HDPs as membrane-agents, possessing a secondary α-helical peptide 
structure, depends on the presence of an ionic milieu that is comparable to the conditions found in 
mammalian body fluids [68-70]. The hydrophilic, cationic part is proposed to initiate electrostatic 
interaction with the negatively charged components of the membrane of microbes; the hydrophobic 
portion is supposed to permit the HDPs to insert into and permeate the membrane.  
The positive charge provides some degree of selectivity towards negatively charged microbial cell 
envelopes and cytoplasmic membranes. These molecules tend to exhibit intrinsic specificity for 
microbial invaders and are relatively much less toxic for the metazoan host's cells. This specificity 
endows the animal with an "innate" immunity, in contrast to the better studied acquired immunity 
conferred by the clonal expansion of B and T cells. The possible importance of this system as a check 
on infection is evident when one considers that most bacteria have generation times of 20-30 minutes Int. J. Mol. Sci. 2009, 10                 
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whereas the mounting of a specific immune response, dependent on the growth of mammalian cells, 
may take days or weeks. Although many cationic peptides demonstrate direct antimicrobial activity 
against bacteria, fungi, eukaryotic parasites and/or viruses [71-73], it has also been established that 
many also have a key modulatory role in the innate immune response and present an important link 
between the innate and adaptive immune responses [74]. 
These HDPs penetrate the outer membrane of Gram-negative bacteria by self-promoted uptake due 
to hydrophobic or electrostatic interactions with lipid A or polyanionic surface LPS (LPS) [11,75]. 
Other mechanisms to kill the bacteria cell are possible due to transmembrane channels, which cause 
changes in permeability of the negatively charged phospholipid membrane. Other models such as 
barrel stave, lipid flip-flop and carpet models are currently discussed as potential ways for HDPs to 
penetrate bacterial membranes [76,77]. Furthermore, DNA and other intracellular targets can be 
affected, leading to cell destruction [77,78]. Many HDPs have additional properties such as   
anti-endotoxic and anti-inflammatory properties, promote apoptosis, influence cell differentiation, 
induce cytokine and chemokine release, stimulate mast cell degranulation, possess chemotactic 
properties and promote wound healing [79-82]. 
As participants in a competent immune response to invading bacteria, HDPs act as immune 
activators by induction of transcription and secretion of cytokines such as IL-8, IL-18, TNF-α,  
GM-CSF, IL-1ß [56,83,84], and induce histamine release from mast cells [85-87]. Certain bacteria are 
better at provoking an overwhelming immune response from the cells of the innate immune system, 
such as monocytes, macrophages, and dendritic cells [80,88], which connect the innate immune system 
with the adaptive immune system. A hyperinflammatory response exposes the organism to the 
pathological processes of sepsis and may lead to organ failure and death [89-91]. In this case, HDPs 
may operate as immune response suppressors to prevent a hyperinflammatory response producing 
severe tissue damage (self-damage) from an overwhelming immune response [23]. 
Endotoxin covers more than 90% of the outer monolayer of Gram-negative bacteria. For the 
microbe, endotoxin works as a protective barrier against antibiotics and for the host immune system it 
is an effector molecule, which is recognized by and activates the innate immune system. In some cases 
life-threatening complications occur caused by antibiotics stimulated Gram-negative bacteria 
endotoxin release [92-94]. The human antimicrobial peptide hCAP18/LL-37 is a multifunctional 
modulator of innate immune responses, its ability to neutralize endoxin inhibits the production of 
proinflammatory cytokines such as TNF-α and IL-6 [23,25]. Scott et al. demonstrated that structurally 
different cationic antimicrobial peptides block the interaction between LPS and LPS-binding protein, 
inhibiting transport and binding of LPS to CD14 receptor [95]. Cirioni et al. reported protective effects 
of hCAP18/LL-37 in lethal sepsis caused by Gram negative bacteria in experimental rat models of 
peritoneal sepsis. The human cathelicidin LL-37 proved to be similarly successful as three commonly 
used antibiotics in lowering lethality [96]. Furthermore, HDPs interact directly with eukaryotic cells 
[43] and can induce alterations in the transcription of hundreds of genes in cells of the innate immune 
system [97]. In addition cathelicidins and defensins promote cell proliferation and wound   
healing [98-102]. 
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5. Current Limitations of Host Defense Peptides 
 
As HDPs have a different mode of action compared to conventional antibiotics, they are less 
affected by multiresistant microbes. However certain HDPs have limitations and some bacteria have 
developed mechanisms to avoid direct killing by HDPs [103,104], through extracellular and 
intracellular resistance mechanisms, including reduction of negative surface charge of the cell wall 
[103,104] and efflux mechanisms [103]. HDPs with a simple linear or α-helical structure are 
susceptible to proteolysis and are targeted by several microbial proteases. Nevertheless, HDPs can be 
prevented from reaching the bacterial cell membrane by bacterial secreted proteins. Examples of 
bacterial secreted proteins include Streptococcus pyogenes with streptococcal inhibitors of 
complement (SIC) proteins, and Staphylococcus aureus with staphylokinase [105,106]. In addition, 
certain HDPs can be actively extruded from bacterial cells, for example by the MtrCDE multiple drug 
resistance exporter in both Neisseria gonorrhoeae and Neisseria meningitidis [107,108]. A potential 
concern that has been noted is that bacteria can also reduce the net anionic charge of their cell 
envelope, reducing the affinity of HDPs to them. However, these mechanisms are relatively inefficient 
compared to those that inhibit the effect of conventional antibiotics [109]. Furthermore, only direct 
killing activity is affected by resistance mechanisms of bacteria whereas immunomodulatory function 
is untouched. 
A new paradigm for the treatment of microbial disease is through the modulation of innate immune 
responses. The importance of HDPs as antimicrobial agents versus their role as immunomodulators is 
somewhat controversial. In addition, the pretence of host defense is relative, as the cytotoxic activities 
of HDPs may have originally evolved to defend the producer bacteria from eukaryotic cell predation 
[110]. HDPs can trigger autoimmunity through immunomodulation. Autoimmunity and host 
antimicrobial immunity are inextricably linked, as effector responses that cause inflammatory tissue 
damage are the same ones that mediate effective host defence. Therefore, immunotherapeutic regimens 
that target common pathways of the immune system inevitably elicit both desirable and undesirable 
consequences. HDPs can also interact with human membranes and this is at least partly responsible for 
cytotoxicity of some peptides at high concentrations [69]. However, distinct composition of 
mammalian membranes, with preferential localisation of anionic phospholipids into the inner leaflet, 
offers some protection [69]. These cytotoxic functional properties of HDPs are generally are thought to 
be associated with their pore-forming activities as multimers in biological membranes leading to   
self-promoted uptake [111,112] a mechanism that has been further described by the Shia-Matsuzaki-
Huang model [113-115]. It is also important to be aware that as HDP hydrophobicity increases, 
generally there is seen a corresponding increase in antimicrobial activity. However, once 
hydrophobicity exceeds a certain level, selectivity between prokaryotic and eukaryotic membranes is 
lost, with a concomitant increase in cytotoxicity [116]. It has been demonstrated in animal models of 
infection that low dose hCAP/LL-37 therapy gives a significant survival benefit over high dose and 
control groups. In both studies, high dose hCAP/LL-37 therapy was associated with a  higher mortality 
rate when compared to both low dose and control groups [117,118]. LL-37 has been shown to have 
non-selective cell toxicity, hemolytic activity and causes DNA fragmentation in cell cultures 
[119,120]. Many other HDPs were shown to be cytotoxic [120]. These setbacks led to increased efforts 
to develop novel synthetic HDPs with less cytotoxic effects and improved antimicrobial activity. Int. J. Mol. Sci. 2009, 10                 
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The concentrations of HDPs found at many body sites (for example, the mucosa) are inconsistent 
with a primary role in direct antimicrobial (killing) action. In addition, HDPs show decreased activity 
at the physiological conditions found in humans due to their sensitivity to both saline solutions and 
monovalent/divalent ions such as Mg
2+ or Ca
2+ in serum [54,121,122]. Hancock et al. observed that 
beta defensin completely loses its activity in concentrations of 100 mM 0.9% NaCl [54]. The weak 
antimicrobial activity under physiologically relevant conditions has been observed with many HDPs 
and has led to increasing discussion as to whether the primary function of certain HDPs is to kill 
bacteria directly [123,124]. Studies have shown that at human physiological conditions HDPs have 
minimal direct antimicrobial activity but retain their immunomodulatory properties to provide in vivo 
protection [121,122].  
 
6. Are We Entering the Post-Antibiotic Era? 
 
Increased levels of HDPs are often found in inflamed or infected skin areas indicating a role of 
these peptides in the protection from infection. Several studies have indicated that HDPs have 
therapeutic potential as topical anti-infectives [73,123-126]. The broad spectrum of antimicrobial 
activity, the low incidence of bacterial resistance and their function as immunomodulatory agents are 
attractive features of HDPs for clinical use. Nevertheless, the morbidity of their cytotoxic effects on 
host cells may limit their use but inform the development of synthetic cationic peptides with 
diminished cytotoxic profiles and enchanced therapeutic properties, such as the ovispirin (sheep HDP) 
–derived designer peptide proline-novispirin G10, which provides broad-spectrum antimicrobial 
activity with low haemolytic and cytotoxic activities [73,125]. Removal of hydrophobic amino acids 
from the N-terminal end of hCAP18/LL-37 holds promise as a template for the reducing saline 
sensitivity but maintaining antimicrobial activity [128]. 
An alternative strategy is gene transfer and the development of target specific HDPs   
(STAMP = Specific target HDPs); they have already shown new ways to combat infection and 
inflammation with HDPs in vitro and in vivo [73,129,130]. Another promising approach is the 
combined application of two or more HDPs [121] as well as the combination of HDPs with commonly 
used antibiotics [132] in an effort to prevent the development of antimicrobial resistance and to 
provide the infected host with optimized antimicrobial therapy [131,132]. 
The clinical application of HDPs is still in its infancy. However, under the few available clinical 
studies [133] four peptides demonstrated clinical effectiveness [109]. In 2000 Levin et al showed 
decreased morbidity in children suffering from meningococcal sepsis, who were treated with the 
designer host defense peptide, rBPI21 (Neuprex), derived from bactericidal/permeability-increasing 
protein [BPI], a human host defense protein produced by polymorphonuclear leukocytes [134]. 
Currently, there are ongoing clinical trials investigating therapeutic effects of rBPI21 in burn patients 
and MSI-78 in diabetic foot ulcers and impetigo. 
The bovine indolicin-derived Migenix MX-226 has already proceeded to a phase 3B study for the 
treatment and prevention of catheter-associated infections [133,109]. Promising candidates for the 
treatment of acne are the designer peptides XOMA 629 and MBI 594AN with bactericidal effects 
against Propionibacterium acnes [135]. This agent is expected to be available for clinical therapy in the 
near future. Int. J. Mol. Sci. 2009, 10                 
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Table 2. Host defense deptides in commercial development. 
Drug  Stage of development  Medical use 
BL2060 (a synthetic compound comprising 
fatty acid and lysine copolymers) 
Lead optimization  Anti-infective 
CSA-13 (cationic steroid (ceragenin) that 
mimics host-defense peptides) 
Preclinical Anti-infective 
CZEN-002 (synthetic 8-mer derived from -
melanocyte–stimulating hormone) 
Phase 2b  Vulvovaginal candidiasis 
HB-50 (synthetic natural peptide mimetic of 
cecropin) 
Preclinical Anti-infective 
HB-107 (19-amino-acid fragment of cecropin 
B) 
Preclinical Wound  healing 
hLF-1-11 (small peptide derived from human 
lactoferrin) 
Phase 2 
Allogeneic bone marrow stem cell 
transplantation–associated infections 
IMX942 (5-amino-acid peptide)  Lead optimization 
Immunomodulation; treatment of fevers 
and neutropenia in chemotherapy patients 
MSI-78  Phase IIIb  Anti-infetive; Wound healing 
Omiganan pentahydrocholoride/ CP-226/MX-
226/CLS001 (12-mer analog of bactolysin) 
Phase 3b 
Prevention of catheter-related infections; 
dermatology-related infections 
MBI 594AN  Preclinical  Anti-infective 
Mersacidin (bacteriocin)  Preclinical Gram-positive  infections 
Plectasin (fungal defensin)  Preclinical 
Systemic anti–Gram positive, especially 
pneumococcal and streptococcal infections 
PAC113 (based on the active segment of 
histatin 5 protein found in human saliva) 
Investigational New 
Drug (IND) approval 
Oral candidiasis 
PTX002 (33-mer peptide) PTX005 (12-mer 
peptide), PTX006 (N-acylated analog of 
PTX005) and PTX007 (a nonpeptidic structura
analog of PTX005) 
Discovery 
Broad-spectrum antimicrobial 
antiendotoxin 
Peptidomimetics (derived from the arylamide, 
calixarene, hydrazide and salicylamide series) 
Discovery/preclinical 
Anti-infectives; antimicrobial polymers 
and coating materials 
rBPI21 Phase  IIIb 
Anti-infective; Allogeneic bone marrow 
stem cell transplantation–associated 
infections; Prevention of burn infections 
XOMA 629  Phase 2a  Anti-infective 
 
7. Conclusions 
 
The emergence of bacterial resistance to antibiotics has led to an increased urgency to explore 
alternative means of combating pathogenic assault. HDPs are rapidly emerging as attractive candidates 
for anti-microbial treatment. HDPs have proven to have an important role in host defenses, with many 
desirable features, and represent an entirely novel class of antimicrobials. The contrasting direct 
antimicrobial and immunomodulatory activities make these peptides valuable in the design of 
alternatively directed therapeutic agents and as tools in dissecting the variations in the mechanisms Int. J. Mol. Sci. 2009, 10                 
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that underpin these diverse activities. In addition, their small size makes them potentially exciting 
prototypes for development as novel immunomodulatory drugs, especially since their collective ability 
to enhance chemokine production, induce chemotaxis, and block endotoxin responses. Future work 
will involve optimizing these HDPs and better characterizing their immunomodulatory properties to 
further illuminate their potential as novel therapeutic agents. In addition as HDPs act via a wide acting 
innate immune system rather than directly on microbe there should not be resistance. There is potential 
for the clinical success of antimicrobial HDPs. And although they do not solve all of the issues created 
by the problem of antibiotic resistance, they do offer a prospectively exciting new tool in the 
clinician’s armamentarium. 
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